ir.oma.aero
OMA Airports - Investor Relations
San Luis Potosí. Ciudad Juárez Plaza. San Luis Potosí Plaza. Why Invest in OMA. Why invest in OMA. Earnings Reports and Conference Calls. Best Corporate Practices Code. We value your opinion. OMA- creating value for our shareholders. Feb 22, 2018. OMA announces Fourth Quarter and Full Year 2017 Operational and Financial Results More. Nov 16, 2017. OMA announces resignation of Chief Financial Officer More. Oct 17, 2017. OMA announces Third Quarter 2017 Operational and Financial Results More. Apr 6, 2018.
ir.omegaproteininc.com
Investor Relations « Omega Protein
News & Media. Science & Innovation. Annual Reports and Proxy Statements. Day High: 15.75. Day Low: 15.24. Prior Close: 15.33. Aug 7, 2015. Delayed 20 min., by eSignal. At Omega Protein, we strive to be a respected leader in every market we serve by providing customers with premium, sustainable products for a healthier world. In pursuit of this mission, we are committed to maximizing shareholder value through the introduction of new and innovative products. Aug 5, 2015. Jul 30, 2015. Day High: 15.75.
ir.omnicare.com
Omnicare : Investors
Omnicare, Inc., a Fortune 500 company based in Cincinnati, Ohio, provides comprehensive pharmaceutical services to patients and providers across the United States. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care settings, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit o...
ir.omnicell.com
Investor Relations | Omnicell, Inc.
Skip to main navigation. Omnicell, Inc., is a leading provider of solutions targeting patient safety and operational efficiency in healthcare facilities. From the point at which a medication arrives at the receiving dock to the time it is administered, Omnicell systems store it, package it, bar code it, order it, issue it, and charge it. Mar 27, 2018. Mercyhealth Adopts Omnicell's XR2 Automated Central Pharmacy System to Enhance Patient Safety. Mar 22, 2018. View all press releases. Mar 27, 2018. IvSTATI...
ir.oncobiologics.com
Oncobiologics - Investor Overview
Regulatory and Clinical Development. GMP Manufacturing Facility Tour. Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony Platform to cost-effectively develop these biosimilars on an accelera...
ir.oncogenex.com
OncoGenex Pharmaceuticals, Inc. - Investor Relations
Scientific Publications and Presentations. Scientific Publications and Events. Aug 4, 2016. OncoGenex Second Quarter 2016 Conference Call. Aug 16, 2016. Oct 13, 2016. OncoGenex ENSPIRIT Trial Conference Call. Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance. Phase 2 in bladder, lung, pancreatic and prostate cancers. Role of Hsp27 and Apatorsen (OGX-427). Aug 1, 2017. Achieve Life Sciences Announces Closing of Merger with OncoGenex Pharmaceuticals. Jun 13, 2017. May 15, 2017.
ir.oncosec.com
Overview
Media & Events. Advancing a lead portfolio of gene therapies for cancer. Platform focused on reversing tumor immune suppression. Phase II clinical programs focused on addressing unmet need of T-cell poor tumors. Clinical data demonstrates proof of concept of the technology. Rapid preclinical development platform. OncoSec Announces Strategic Relocation Of Office And Laboratories. Mar 20, 2018. Jan 31, 2018. Sign up for email alerts. Be the first to receive breaking news.
ir.oncothyreon.com
Overview - Oncothyreon
Annual Reports and Proxy. We are committed to serving the best interests of our shareholders. If you require assistance or have questions regarding the key shareholder information and financial reports available here please contact. 027 (- 7.56%). 4:00 PM ET on Aug 7, 2015. Delayed at least 20 minutes. Aug 6, 2015. Oncothyreon Reports Second Quarter 2015 Financial Results. Jul 30, 2015. Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call. View all recent releases ».
ir.onehorizongroup.com
IR Overview :: One Horizon Group, Inc. (OHGI)
Carrier Products and Services. One Horizon's Carrier Technology. Billing and Provisioning Platform. Rapid Deployment and Simple Integration. The Aishuo Mobile App. Enterprise Products and Services. One Horizon's Enterprise Technology. Rapid Deployment and Simple Integration. Limitations of Mobile VoIP. Horizon Library For Developers. One Horizon Group, Inc. (NASDAQ: OHGI). SeeThru Equity Research Report. Outstanding: 32,921,533. As of May 15, 2015). One Horizon Group, Inc. Tierney Building - T1017.
ir.oneok.com
Investor Information - ONEOK - Investor Relations Home
Q2 ONEOK Inc. and ONEOK Partners Earnings Conference Call. 160;at 11:00 am ET. Q2 ONEOK Inc. and ONEOK Partners Earnings Conference Call. Wednesday, August 5, 2015 . 11:00 am ET . Click here for webcast. Click here to add this event to your calendar. ONEOK is a FORTUNE 500 company and is included in Standard and Poor's (S&P) 500 Stock Index. View 2014 Annual Report. ONEOK and ONEOK Partners to Participate in the Tuohy Brothers Annual Energy Conference. ONEOK Announces Second-quarter 2015 Results. Form 1...
ir.oneokpartners.com
Investor Information - ONEOK Partners - Investor Relations Home
Q2 2015 ONEOK Inc. and ONEOK Partners Earnings Conference Call. 160;at 11:00 am ET. Q2 2015 ONEOK Inc. and ONEOK Partners Earnings Conference Call. Wednesday, August 5, 2015 . 11:00 am ET . Click here for webcast. Click here to add this event to your calendar. Its general partner is a wholly owned subsidiary of ONEOK, Inc. A pure-play publicly traded general partner, which owns 36.8 percent of the overall partnership interest, as of June 30, 2015. More. View 2014 Annual Report. Form 8-K Report of unsche...
SOCIAL ENGAGEMENT